The rising global incidence of cervical cancer is estimated to have affected more than 600,000 women, and nearly 350,000 women are predicted to have died from the disease in 2020 alone. Novel advances in cancer prevention, screening, diagnosis and treatment have all but reduced the burden of cervical cancer in developed nations. Unfortunately, cervical cancer is still the number one gynecological cancer globally. A limiting factor in managing cervical cancer globally is access to healthcare systems and trained medical personnel. Any methodology or procedure that may simplify or assist cervical cancer screening is desirable. Herein, we assess the use of artificial intelligence (AI)-assisted colposcopy in a tertiary hospital cervical diagnostic pathology unit. The study group consisted of 48 women (mean age 34) who were referred to the clinic for a routine colposcopy by their gynecologist. Cervical images were taken by an EVA-Visualcheck ^TM colposcope and run through an AI algorithm that gave real-time binary results of the cervical images as being either normal or abnormal. The primary endpoint of the study assessed the AI algorithm’s ability to correctly identify histopathology results of CIN2+ as being abnormal. A secondary endpoint was a comparison between the AI algorithm and the clinical assessment results. Overall, we saw lower sensitivity of AI (66.7%; 12/18) compared with the clinical assessment (100%; 18/18), and histopathology results as the gold standard. The positive predictive value (PPV) was comparable between AI (42.9%; 12/28) and the clinical assessment (41.8%; 18/43). The specificity, however, was higher in the AI algorithm (46.7%; 14/30) compared to the clinical assessment (16.7%; 5/30). Comparing the congruence between the AI algorithm and histopathology results showed agreement 54.2% of the time and disagreement 45.8% of the time. A trained colposcopist was in agreement 47.9% and disagreement 52.1% of the time. Assessing these results, there is currently no added benefit of using the AI algorithm as a tool of speeding up diagnosis. However, given the steady improvements in the AI field, we believe that AI-assisted colposcopy may be of use in the future.

There is accumulating evidence on the perinatal aspects of COVID-19, but available data are still insufficient. The reports on perinatal aspects of COVID-19 have been published on a small group of patients. Vertical transmission has been noted. The SARS-CoV-2 genome can be detected in umbilical cord blood and at-term placenta, and the infants demonstrate elevated SARS-CoV-2-specific IgG and IgM antibody levels. In this work, the analysis of clinical characteristics of RT-PCR SARS-CoV-2-positive pregnant women and their infants, along with the placental pathology correlation results, including villous trophoblast immunoexpression status for SARS-CoV-2 antibody, is presented. RT-PCR SARS-CoV-2 amniotic fluid testing was performed. Neonatal surveillance of infection status comprised RT-PCR testing of a nasopharyngeal swab and the measuring of levels of anti-SARS-CoV-2 in blood serum. In the initial study group were 161 pregnant women with positive test results. From that group, women who delivered during the hospital stay were selected for further analysis. Clinical data, laboratory results, placental histomorphology results, and neonatal outcomes were compared in women with immunohistochemistry (IHC)-con SARS-CoV-2-positive and IHC SARS-CoV-2-negative placentas (26 cases). A positive placental immunoprofile was noted in 8% of cases (n = 2), whereas 92% of cases were negative (n = 24). Women with placental infection proven by IHC had significantly different pathological findings from those without. One infected neonate was noted (n = 1; 4%). Infection was confirmed in perinatal autopsy, as there was the intrauterine fetal demise. The potential course of the infection with the risk of vertical transmission and implications for fetal–neonatal condition is critical for proper clinical management, which will involve comprehensive, multidisciplinary perinatal care for SARS-CoV-2-positive patients.

Introduction: Postpartum haemorrhage (PPH) is a leading cause of maternal mortality worldwide, particularly in low- and middle-income countries, complicating 1% to 10% of deliveries. Despite improvement in prevention and management, variations in PPH definitions and measurement methods contribute to challenges in accurately assessing its incidence, with up to 90% of PPH-related deaths in high-income countries deemed avoidable through timely intervention. Oxytocin is the primary drug administered during labour or miscarriage, causing an increase in uterine muscle tone, which reduces bleeding and the risk of complications. The aim of the study was to assess the rate of oxytocin use by paramedics for out-of-hospital births in Poland and to verify adherence to WHO-recommended protocols for preventing postpartum haemorrhage in emergency prehospital settings. Methods: We conducted a cross-sectional study using data from the Polish Central System for Emergency Medical Services Missions Monitoring covering all EMS interventions nationwide from 2018 to 2023. The study included cases where oxytocin was administered during EMS interventions for pregnant women, identified through ICD-10 codes (O30–O92), with 62 verified cases meeting the inclusion criteria. Results: Over 6 years, oxytocin was administered in 62 cases when paramedics responded to emergencies involving pregnant women. The mean age of the patients to whom the oxytocin was administered was 29.48 years (SD = 6.25) and ranged from 15 to 43 years. Conclusions: Oxytocin is rarely administered by EMS teams at the prehospital stage. Oxytocin should be considered for incorporation into the set of medications that EMS teams can administer in prehospital settings. There is a need to train EMS teams in the management of pregnancy-related emergencies in accordance with the current medical guidelines.

Background/Objectives: Respiratory syncytial virus (RSV) is a major cause of severe lower res-piratory tract infections in infants, particularly in vulnerable populations such as preterm new-borns and those with underlying health conditions. The approval of the RSVpreF vaccine for pregnant individuals offers a new strategy to reduce the burden of RSV-associated illness in newborns. The aim of this study was to assess RSV vaccination coverage among pregnant wom-en, identify factors contributing to vaccination hesitancy, and evaluate the knowledge of the bene-fits of vaccination among patients in Poland. Methods: The study was conducted on 668 re-spondents from Poland. The study utilized an original, anonymous questionnaire consisting of 23 questions, which was distributed via social media platforms from July 25 to August 1, 2024. Par-ticipants, including women who had recently given birth or were about to, were recruited through Facebook groups and Instagram. Results: We confirmed that responders with medical back-grounds had statistically greater knowledge about RSV than non-medical individuals. Addi-tionally, indivudals with medical medical backgrounds were more likely to receive the RSV vac-cination during pregnancy, as were patients who obtained vaccination information directly from their physician. Furthermore, a key finding was that patients who had previously received vac-cinations for other diseases, such as influenza and pertussis, were more likely to opt for RSV vac-cination. Conclusions: Vaccination against RSV during pregnancy is a crucial method for safe-guarding newborns from infection and its severe complications. Awareness of RSV and vaccina-tion rates among pregnant women remains low, necessitating educational initiatives and public health campaigns to improve coverage.

Interventional radiology (IR) has reshaped contemporary management strategies for selected gynecological and obstetric disorders by introducing minimally invasive, organ-sparing therapeutic alternatives to conventional surgical approaches. This review examines the current applications of IR in the treatment of symptomatic uterine fibroids, pelvic congestion syndrome, placenta accreta spectrum, cesarean scar pregnancy, and selected gynecological malignancies requiring palliative or preoperative embolization. In addition, selected vascular conditions in pregnancy, including visceral and cerebral aneurysms, are discussed due to their high-risk clinical profile and growing relevance for endovascular management. These entities were chosen because of their substantial clinical relevance, risk of severe complications, and the expanding body of evidence supporting endovascular management. Techniques such as uterine artery embolization and ovarian vein embolization are associated with high technical success and meaningful symptom reduction, while simultaneously decreasing hospitalization time, perioperative morbidity, and convalescence compared with traditional surgery. In complex obstetric scenarios—including placenta accreta spectrum and splenic artery aneurysm—prophylactic balloon occlusion and endovascular embolization may significantly limit life-threatening hemorrhage and improve maternal prognosis in appropriately selected patients when implemented within a multidisciplinary setting; for splenic artery aneurysm in particular, this evidence currently derives from case reports and small case series rather than comparative trials. Imaging modalities, including ultrasonography, computed tomography, magnetic resonance imaging, and angiography, are integral to diagnosis, patient qualification, procedural planning, and post-intervention monitoring. Although existing data generally confirm the safety and efficacy of interventional techniques, important limitations persist, including heterogeneous study populations, relatively small cohorts, and insufficient long-term reproductive follow-up. Greater standardization of clinical indications and procedural protocols, ongoing technological advancement, and well-designed multicenter trials are required to consolidate the evidence base. In gynecologic oncology, embolization techniques may provide effective hemorrhage control and facilitate surgical treatment in selected patients. In addition, uterine artery embolization has emerged as an important uterus-preserving adjunct in the management of cesarean scar pregnancy, although long-term reproductive (fertility) outcome data remain limited. IR is becoming an increasingly important component of modern gynecological care, supporting individualized, uterus-preserving, and less invasive therapeutic strategies; fertility preservation specifically is an important goal that, for several of the indications discussed, remains incompletely proven by long-term reproductive-outcome data.